Cheng, Chen and Jiang, Ying and Lu, Xiaodong and Gu, Fu and Kang, Zhuang and Dai, Yongqiang and Lu, Zhengqi and Hu, Xueqiang (2016) The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurology, 16 (1). ISSN 1471-2377

Access from the University of Nottingham repository:
http://eprints.nottingham.ac.uk/47351/1/The%20role%20of%20anti-aquaporin%204%20antibody%20in%20the%20conversion%20of%20acute%20brainstem%20syndrome%20to%20neuromyelitis%20optica.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the Creative Commons Attribution licence and may be reused according to the conditions of the licence. For more details see:
http://creativecommons.org/licenses/by/2.5/

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk
The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica

Chen Cheng†, Ying Jiang‡*, Xiaodong Lu†, Fu Gu, Zhuang Kang†, Yongqiang Dai‡, Zhengqi Lu‡ and Xueqiang Hu‡

Abstract

Background: Acute brainstem syndrome (ABS) may herald multiple sclerosis (MS), neuromyelitis optica (NMO), or occur as an isolated syndrome. The aquaporin 4 (AQP4)-specific serum autoantibody, NMO-IgG, is a biomarker for NMO. However, the role of anti-AQP4 antibody in the conversion of ABS to NMO is unclear.

Methods: Thirty-one patients with first-event ABS were divided into two groups according to the presence of anti-AQP4 antibodies, their clinical features and outcomes were retrospectively analyzed.

Results: Fourteen of 31 patients (45.16 %) were seropositive for NMO-IgG. The 71.43 % of anti-AQP4 (+) ABS patients converted to NMO, while only 11.76 % of anti-AQP4 (-) ABS patients progressed to NMO. Anti-AQP4 (+) ABS patients demonstrated a higher IgG index (0.68 ± 0.43 vs 0.42 ± 0.13, \( p < 0.01 \)) and Kurtzke Expanded Disability Status Scale (4.64 ± 0.93 vs 2.56 ± 0.81, \( p < 0.01 \)) than anti-AQP4 (-) ABS patients. Area postrema clinical brainstem symptoms occurred more frequently in anti-AQP4 (+) ABS patients than those in anti-AQP4 (-) ABS patients (71.43 % vs 17.65 %, \( p = 0.004 \)). In examination of magnetic resonance imaging (MRI), the 78.57 % of anti-AQP4 (+) ABS patients had medulla-predominant involvements in the sagittal view and dorsal-predominant involvements in the axial view.

Conclusions: ABS represents an inaugural or limited form of NMO in a high proportion of anti-AQP4 (+) patients.

Keywords: Acute brainstem syndrome, Anti-aquaporin 4 antibody, Neuromyelitis optica, Magnetic resonance imaging
were retrospectively analyzed. All the patients involved in this study fulfilled the following inclusive criteria: 1) test for NMO-IgG; 2) single clinical episode of ABS associated with relevant brainstem MRI lesions; 3) no other neurologic signs or symptoms which suggested the diagnosis of MS or NMO before NMO-IgG testing. Exclusion criteria included previous or concomitant systemic autoimmune diseases, metabolic etiology, vascular disorders and infections. All the patients were negative for HIV antibody.

The subjects provided written informed consent. This study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the institution’s ethics committee. Lumbar puncture was also performed with informed consent.

Data collection
Clinical features and outcomes including gender, age at onset, duration, relapse times, annualized recurrence rate, clinical manifestations, and magnetic resonance imaging (MRI) findings were recorded in details. Analysis of cerebrospinal fluid (CSF), serum anti-AQP4 test and examinations of magnetic resonance imaging (MRI) were performed within 2 weeks after attack of brainstem symptoms and before treatment. The diagnosis of NMO, NMOSD and MS was based on Wingerchuk’s criteria in 2006 [18], International consensus diagnostic criteria for NMOSD in 2015 [1] and McDonald’s criteria in 2010 [19] respectively. These symptoms, such as area postrema clinical syndrome (including intractable hiccups, nausea and vomiting), diplopia, and bulbar dysfunctions, were regarded as the manifestation of brainstem symptoms. A relapse of ABS was defined as definite brainstem symptoms of neurological dysfunction that lasted more than 24 h, together with relevant brainstem lesions after ruling out infective agents. Symptoms occurring within 1 month after the initial symptoms of relapse were considered to be part of the same episode. The neurological disability of the patients was assessed using the Kurtzke Expanded Disability Status Scale (EDSS) [20]. A corticosteroid (1000 mg methyl prednisone, administered intravenously for five consecutive days) was prescribed in the acute stage and some patients received azathioprine in the remission stage when developed as NMO.

AQP4 and oligoclonal bands testing
AQP4 antibodies were determined using a cell-based assay on an AQP4-transfected cell line from a commercial BIOCHIP kit (EUROIMMUN AG, Lübeck, Germany) according to the manufacturer’s instructions. The CSF oligoclonal bands (OCB) detection method used in our laboratory was an isoelectric focusing technique combined with the avidin-biotinperoxidase complex method.

MRI scanning
Brain and spinal cord MRI scans were carried out for all patients using a GE 1.5 T MR scanner (General Electric, Milwaukee, WI, USA). The slice thickness of the axial scans was between 3 and 5 mm. Conventional MRI protocols were used: T1 with and without gadolinium enhancement (400/15.5 ms, TR/TE) and T2 (2500–3500/100 ms, TR/TE) in spinal cord MRI; and T1 with and without gadolinium enhancement (2128–2300/11.6–12.4 ms, TR/TE), T2 (4600–4640/97.8–102 ms, TR/TE), and fluid-attenuated inversion recovery (FLAIR) (8800/120 ms, TR/TE) in brain MRI. A cross-sectional evaluation was also performed on all MRI scans of the brain, and brainstem lesions were classified as either having a ventral pattern, a dorsal pattern. The spinal cord was segmented into cervical and thoracolumbar regions. LETM is a spinal cord lesion that extends over 3 or more vertebral segments. All MRI scans were carried out prior to use of corticosteroid, immunomodulatory or immunosuppressive treatment. An experienced neuroradiologist and a neurologist, both of whom were blinded to the diagnostic categorization and the patients’ clinical features, each analyzed all of the MRI scans. The final assessments were made by consensus.

Statistical analysis
All statistical analyses were performed using Statistical Program for Social Sciences (SPSS) statistical software (version 16.0; Chicago, IL, USA). For each set of values, data were expressed as the means ± standard deviation (SD). Categorical variables were compared using Fisher’s exact test. Non-categorical variables were compared using the Mann-Whitney U test. Survival was estimated according to the Kaplan-Meier method. The primary study endpoint was the time to NMO conversion, as indicated by the Wingerchuk’s criteria [18]. The log-rank test was used to compare the survival analysis between anti-AQP4 (+) and anti-AQP4 (-) ABS patients. All p-values were two-tailed, with values of < 0.05 considered significant. This study was an exploratory study so that no adjustment for multiple comparisons was made.

Results
The data of 352 patients in our database were reviewed between 2009 and 2011. A total of 31 patients who were enrolled in this study satisfied the diagnostic criteria: 14 anti-AQP4 (+) patients with ABS and 17 anti-AQP4 (-) patients with ABS. The details of the enrollment process can be seen in the flowchart (Fig. 1).

Clinical characteristics
In 31 ABS patients (female-male ratio is 5.2:1) 14 (45.16%) were positive for anti-AQP4 antibodies (Table 1). The mean age of onset for anti-AQP4 (+) ABS patients
(31.21 ± 8.81 years) was similar to that of anti-AQP4 (-) patients (30.82 ± 8.55 years). According to Wingerchuk criteria in 2006, 71.43 % anti-AQP4 (+) patients (10/14) converted to NMO while only 11.76 % anti-AQP4 (-) ABS patients (2/17) converted to NMO within the follow-up after first-event brainstem symptoms (p < 0.01). The 100 % anti-AQP4 (+) patients (14/14) converted to NMOSD while only 17.65 % anti-AQP4 (-) ABS patients (3/17) converted to NMOSD (p < 0.001) according to International consensus diagnostic criteria for NMOSD in 2015. The cumulative NMO conversion probability was significantly higher in anti-AQP4 (+) patients than in anti-AQP4 (-) patients (Table 1, OR 18.75; 95 % CI 2.871 to 122.452; p = 0.001).

Table 1 Comparison of clinical features between anti-AQP4 (+) and anti-AQP4 (-) patients with ABS

| Clinical features                  | Anti-AQP4 (+) | Anti-AQP4 (-) | Total     | P value |
|-----------------------------------|---------------|---------------|-----------|---------|
| Female/male ratio                 | 1:13          | 4:13          | 5:26      | 0.344   |
| Age of onset (±SD) (years)        | 31.21 ± 8.81  | 30.82 ± 8.55  | 31.00 ± 8.52 | 0.902   |
| Duration of follow-up (months)    | 46.35 ± 13.80 | 40.00 ± 11.30 | 44.51 ± 14.86 | 0.169   |
| Number of episodes                | 3.71 ± 0.73   | 2.41 ± 1.54   | 3.00 ± 1.39 | 0.005   |
| Annual relapse rate               | 1.05 ± 0.40   | 0.72 ± 0.40   | 0.87 ± 0.43 | 0.031   |
| NMOSD                             | 14/14 (100 %) | 3/17 (17.65 %) | 17/31 (54.84 %) | <0.001  |
| NMO                               | 10/14 (71.43 %) | 2/17 (11.76 %) | 12/31 (38.71 %) | 0.001   |
| MS                                | 0/14 (0.00 %) | 7/17 (41.17 %) | 7/31 (22.58 %) | 0.007   |
| Monophasic                        | 0/14 (0.00 %) | 7/17 (41.17 %) | 7/31 (22.58 %) | 0.007   |
| CSF examinations                  |               |               |           |         |
| Total protein (mg/dl, ±SD)        | 0.30 ± 0.10   | 0.25 ± 0.12   | 0.27 ± 0.11 | 0.204   |
| Cell counts (number/μl, ±SD)      | 11.29 ± 4.27  | 8.47 ± 2.07   | 9.74 ± 2.21 | 0.07    |
| Pleocytosis >50WBC/μl (%)          | 2/14          | 0/17          | 2/31      | 0.196   |
| IgG index                         | 0.68 ± 0.07   | 0.42 ± 0.13   | 0.54 ± 0.17 | <0.01   |
| Oligoclonal bands                 | 1/14 (7.14 %) | 1/17 (5.88 %) | 2/31 (6.45 %) | 0.708   |
| EDSS a                            | 3 (2–4)       | 3 (2–3)       | 3 (2–4)   | 0.141   |
| EDSS b                            | 5 (3–7)       | 2.5 (1.5–4.5) | 3.5 (1.5–7) | <0.001  |

ABS acute brainstem syndrome, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disorder, MS multiple Sclerosis, ON optic neuritis, CSF cerebrospinal fluid, EDSS Kurtzke Expanded Disability Status Scale, a, EDSS scores at the first attack; b, EDSS scores of the last visit of follow-up
Brainstem symptoms
The brainstem symptoms of 31 ABS patients were listed in Table 2. Five anti-AQP4 (+) patients (35.71 %) experienced recurrent brainstem symptoms before the attacks of ON or myelitis, while only one anti-AQP4 (-) patients (5.88 %, \( p = 0.05 \)) had more than one brainstem attacks. Area postrema clinical brainstem symptoms, such as hiccup (29.41 % vs 5.88 %, \( p = 0.05 \)), nausea and vomiting (64.28 % vs 17.65 %, \( p = 0.011 \)), occurred more frequently in anti-AQP4 (+) patients than those in anti-AQP4 (-) patients.

MRI examinations
Brain and spinal cord MRI examinations were conducted for all patients. On the sagittal section of brain MRI, the lesions were more frequently occurred in the medulla of anti-AQP4 (+) patients than those in anti-AQP4 (-) patients (78.75 % vs 35.29 %, \( p = 0.019 \)). However, there were no statistical differences in the other parts of brainstem between these two groups, such as midbrain and pons (Fig. 2, Table 3). Dorsal-predominant lesions were involved more frequently in anti-AQP4 (+) patients than in the anti-AQP4 (-) patients (58.33 % vs 22.22 %, \( p = 0.01 \)). The lesions in periependymal region were found more common in anti-AQP4 (+) patients than in anti-AQP4 (-) patients (35.29 % vs 7.14 %, \( p = 0.049 \) (Fig. 3, Table 3). And the lesions in area postrema were found in 4 anti-AQP4 (+) patients and 3 anti-AQP4 (-) patients (28.57 % vs 17.64 %, \( p = 0.383 \)) (Fig. 2, Table 3). None of the spinal cord lesions were detected in the two groups when the initial episode of ABS. However, during the follow-up, segments of spinal cord lesions were longer in anti-AQP4 (+) patients than in anti-AQP4 (-) patients (5 vs 2, \( p = 0.001 \)) (Table 4). LETM were also found more commonly in anti-AQP4 (+) patients (64.29 % vs 17.65 %, \( p = 0.012 \)) at the duration of follow-up (Table 4).

CSF examinations
CSF specimens were obtained from all patients at the acute stage (Table 1). The protein concentrations in CSF of anti-AQP4 (+) patients (0.30 ± 0.10 mg/dl) were similar with those of anti-AQP4 (-) patients (0.25 ± 0.12 mg/dl). Anti-AQP4 (+) patients had a slightly higher number of white blood cells (WBCs) in CSF (11.29 ± 4.27) than anti-AQP4 (-) patients (8.47 ± 0.72). However, the values of IgG index in anti-AQP4 (+) patients were significantly higher than those of anti-AQP4 (-) patients (0.68 ± 0.07 vs 0.42 ± 0.13, \( p < 0.01 \)). Only one anti-AQP4 (+) ABS patient and one anti-AQP4 (-) ABS patient were positive for OCBs in CSF.

Prognosis in ABS patients
All the patients were followed up at least 2 years after the first episode of ABS. The median duration of follow-up was 42 months (24–65 months). 7/31 (22.58 %) of patients did not show a second episode during the follow-up period, 12/31(38.70 %) of patients developed to NMO, 17/31(54.84 %) of patients converted to NMOSD, and 7/31(22.58 %) of patients converted to MS. In the follow-up duration, the mean annual relapse rates of anti-AQP4 (+) patients were significantly higher than those of anti-AQP4 (-) patients (1.05 ± 0.40 vs 0.72 ± 0.40, \( p = 0.031 \)) (Table 1). Although the EDSS scores at the first attack were similar between two groups, anti-AQP4 (+) patients presented a significantly higher EDSS scores than anti-AQP4 (-) patients at the last visit of follow-up [5(3–7) VS 2.5(1.5–4.5), \( p < 0.01 \)]. Kaplan-Meier survival analysis showed that the risk of developing to NMO in anti-AQP4 (+) patients were higher than those in anti-AQP4 (-) patients.

### Table 2 Comparison of brainstem symptoms between anti-AQP4 (+) and anti-AQP4 (-) patients with ABS

| Onset symptoms                        | Anti-AQP4 (+) | Anti-AQP4 (-) | Total | \( P \) value |
|---------------------------------------|---------------|---------------|-------|---------------|
| Anti-AQP4 (+)                          | Anti-AQP4 (-) | Total         |       |               |
| Diplopia                              | 6/14 (42.86 %)| 8/17 (47.06 %)| 14/31 (45.16 %)| 0.551         |
| Area postrema clinical syndrome       | 10/14 (71.43 %)| 3/17 (17.65 %)| 13/31 (41.94 %)| 0.004         |
| Intractable hiccup                    | 5/14 (39.41 %)| 1/17 (5.88 %) | 6/31 (19.35 %)| 0.05          |
| Nausea and vomiting                   | 9/14 (64.28 %)| 3/17 (17.65 %)| 12/31 (38.71 %)| 0.011         |
| Bulbar dysfunction                    | 5/14 (35.71 %)| 6/17 (35.29 %)| 11/31 (35.48 %)| 0.636         |
| Dysarthria                            | 1/14 (7.14 %) | 3/17 (17.65 %)| 4/31 (12.90 %)| 0.378         |
| Dysphagia                             | 2/14 (14.29 %)| 4/17 (23.53 %)| 6/31 (19.35 %)| 0.429         |
| Alalia                                | 2/14 (14.29 %)| 0/17 (0 %)    | 2/31 (6.45 %) | 0.196         |
| Vertigo                               | 4/14 (28.57 %)| 7/17 (41.18 %)| 11/31 (35.48 %)| 0.364         |
| Facial paralysis                      | 2/14 (14.29 %)| 5/17 (29.41 %)| 7/31 (22.58 %)| 0.287         |
| Ataxia                                | 3/14 (21.43 %)| 7/17 (41.18 %)| 7/31 (22.58 %)| 0.218         |
| Quadriplegia                          | 2/14 (14.29 %)| 1/17 (5.88 %) | 3/31 (9.68 %) | 0.425         |

ABS acute brainstem syndrome

---

Cheng et al. BMC Neurology (2016) 16:203
significantly higher than that in anti-AQP4 (-) patients (log rank 5.23, $p = 0.012$) (Fig. 4).

**Discussion**

NMO frequently begins with an acute or subacute episode of ON or myelitis. However, brainstem symptoms in NMO were not rare [8, 10–12, 17]. According to the previous studies, brainstem symptoms have recently been described in NMO as well as in NMOSD [10, 12, 13, 17, 21]. In 17.05–30.61 % NMO patients, brainstem symptoms even act as the sole manifestation [14, 17]. “Brainstem symptoms with anti-AQP4 antibodies” has also been recommended in the latest diagnostic criteria for NMOSD [1]. Various brainstem symptoms such as area postrema clinical brainstem symptoms (including intractable hiccups, nausea and vomiting), diplopia, and bulbar dysfunctions attributed to lesions in the dorsal region of the medullar and the pons surrounding the fourth ventricle could be the first manifestation of symptoms [9, 10, 12, 14]. Our results demonstrated that area

### Table 3 Comparison of brainstem MRI between anti-AQP4 (+) and anti-AQP4 (-) patients when the initial episode of ABS

| MRIs                  | Anti-AQP4 (+) (n = 14) | Anti-AQP4 (-) (n = 17) | Total (n = 31) | $P$ value  |
|-----------------------|------------------------|------------------------|----------------|------------|
| **Brainstem lesions** |                        |                        |                |            |
| **Sagittal view**     |                        |                        |                |            |
| Pons                  | 6/14 (42.86 %)          | 8/17 (47.06 %)         | 14/31 (45.16 %)| 0.551      |
| Midbrain              | 3/14 (21.43 %)          | 5/17 (29.41 %)         | 8/31 (25.81 %) | 0.466      |
| Medulla               | 11/14 (78.57 %)         | 6/17 (35.29 %)         | 17/31 (54.84 %)| 0.019      |
| **Axial view**        |                        |                        |                |            |
| Dorsal                | 11/14 (78.57 %)         | 7/17 (41.17 %)         | 18/31 (58.06 %)| 0.04       |
| Ventral               | 3/14 (21.43 %)          | 10/17 (58.82 %)        | 13/31 (41.94 %)| 0.04       |
| Periependymal region  | 3/14 (21.43 %)          | 1/17 (5.88 %)          | 4/31 (12.90 %) | 0.228      |
| Area postrema         | 4/14 (28.57 %)          | 3/17 (17.64 %)         | 7/31 (22.58 %) | 0.383      |

ABS acute brainstem syndrome
postrema clinical brainstem symptoms in anti-AQP4 (+) ABS patients were more frequent than those in anti-AQP4 (-) ABS patients. Intractable hiccups, nausea, and vomiting have been reported as unique symptoms in NMO due to the involvement of the pericanal region in the medulla oblongata, which included the areas postrema, nucleus tractus solitaries where the putative hiccups and vomiting centres are located [13, 14]. In our study, intractable hiccups, nausea, and vomiting occur in 71.43 % anti-AQP4 (+) ABS patients, which are more frequent than in anti-AQP4(-) ABS patients. Previous study also confirmed that intractable hiccups, nausea, and vomiting are clinical markers for the early phase of an exacerbation in NMO [22]. In addition, anti-AQP4 (+) ABS patients are prone to have recurrent brainstem symptoms before attacks of ON or myelitis.

In addition to clinical features, the distribution of brainstem lesions of anti-AQP4 (+) ABS patients also is different from anti-AQP4 (-) ABS patients. Although the midbrain and pons in the sagittal view are involved both in anti-AQP4 (+) ABS patients and anti-AQP4 (-) ABS patients, the medulla segments are more frequently involved in anti-AQP4 (+) ABS patients. In the axial view, anti-AQP4 (+) ABS patients present dorsal-predominant involvement, which is consistent with our previous report [23]. In AQP4 (+) ABS patients, majority of the

Table 4 Comparison of brain and spinalcord MRI between anti-AQP4 (+) and anti-AQP4 (-) patients during follow-up

| MRIs                      | Anti-AQP4 (+) | Anti-AQP4 (-) | Total | P value |
|---------------------------|---------------|---------------|-------|---------|
| Brain MRIs                | n = 14        | n = 17        | n = 31|         |
| Lesions in other brain regions |               |               |       |         |
| Juxtacortical             | 0/14 (0)      | 2/17 (11.76 %)| 2/31 (6.45 %) | 0.488 |
| Subcortical               | 1/14 (7.14 %) | 5/17 (29.41 %)| 6/31 (19.35 %)| 0.185 |
| Infratentorial            | 14/14 (100 %) | 17/17 (100 %) | 31/31 (100 %) |       |
| Spinal cord MRI           |               |               |       |         |
| Segments                  | 5 (3–7)       | 2 (0–4)       | 3.5 (0–8) | 0.001 |
| Cervical                  | 10/14 (71.43 %)| 13/17 (76.47 %)| 23/31 (74.19 %)| 0.750 |
| Thoracic                  | 7/14 (50 %)   | 5/17 (29.41 %)| 12/31 (38.71 %)| 0.242 |
| Cervical and thoracic     | 3/14 (21.43 %)| 1/17 (5.88 %) | 4/31 (12.90 %)| 0.199 |
| LETM                      | 9/14 (64.29 %)| 3/17 (17.65 %)| 12/31 (38.71 %)| 0.012 |
| Meet Barkhof criteria     | 0/14 (0 %)    | 5/17 (29.41 %)| 5/31 (16.13 %)| 0.185 |
Lesions (78.57 %) are observed in the medulla including 28.57 % lesions occurring in the area postrema. There is an agreement between MRI findings and clinical presentation of brainstem lesions. This study supports that the brainstem, especially medulla and area postrema, is the important region of attack in NMO [11, 17].

NMO-IgG has been proved to be highly specific and moderately sensitive to NMO. The prevalence of anti-AQP4 antibodies in NMO patients ranged from 50–60 % [3, 24–26]. However, NMO-IgG is not restricted to these patients fulfilling all criteria for a definite diagnosis of NMO [27–29]. This antibody is also identified in partial syndromes, the frequency of anti-AQP4 in acute partial transverse myelitis is 4.5 % [30], while 26.9 % in recurrent ATM [31], increasing to 37.9–60 % in LETM [27, 31, 32] and 20 % in recurrent ON [33], 5.8 % in acute monosymptomatic ON [34]. Our study provided that the frequency of anti-AQP4 in ABS is 45.16 %. Currently, sensitive marker(s) to predict the conversion of ABS to NMO are still absent. Our results found that 100 % of the anti-AQP4 (+) ABS patients experience clinical relapse, and 71.43 % of anti-AQP4 (+) ABS patients convert to NMO in the following 3 years, while only 11.76 % of the anti-AQP4 (-) ABS patients convert to NMO, and the cumulative NMO conversion probability is significantly higher in anti-AQP4 (+) ABS patients than that in anti-AQP4 (-) ABS patients. These results are similar to those patients with ON or LETM as the initial presentation, which also demonstrated a rapid NMO conversion in the first 2 years after the initial episode [32, 35]. The results suggested that anti-AQP4 antibodies may be useful for diagnosis and prognosis of patients who presented with isolated ABS. Moreover, 29.42 % of anti-AQP4 (+) ABS patients experience recurrent brainstem symptoms before attack of ON or myelitis, which suggested that anti-AQP4 antibody associated recurrent brainstem symptoms should be paid more attention. The anti-AQP4 (+) ABS patients are at high risk for development of severe disability.

Several studies have also identified a new antigenic target, myelin oligodendrocytic glycoprotein (MOG), as being of interest in seronegative AQP4 patients [36]. Compared with AQP4-positivity patients, serum MOG antibodies do have a distinct clinical phenotype from AQP4-positivity NMO that is characterized by fewer relapses, a better clinical outcome, and a wider spectrum of MRI features, which may suggest a sort of disease distinct from NMO or MS [37–39]. This antibody is found in around 20 % of AQP4-seronegative patients. MOG testing was not performed in this study, therefore we can’t exclude the bias of MOG-seropositive patients in our AQP4 negative cohort. However, brainstem lesions, which are a hallmark of AQP4-seropositive NMO/NMOSD, occur less frequently in MOG-seropositive patients [38, 40]. Moreover, the primary endpoint of our study is the conversion of typical NMO. Therefore, this would make little impact on our results.

Therapy of NMO should be initiated early. Azathioprine and rituximab are suggested as first-line treatments [41]. In patients with NMOSD, IFN-β treatment [42], glatiramer acetate [43], natalizumab [44] and fingolimod (FTY720) [45] are ineffective for preventing relapses or fail to control disease activity. In our study, no patients received the above treatments, which might have treatment effects on accumulative NMO conversion probability. Therefore, the risk of conversion to NMO in anti-AQP4 (+) ABS patients seems higher in the first 2 years based on this study. We recommend that all patients with ABS make test for NMO-IgG and that seropositive patients receive immunosuppressive treatments which are effective in reducing NMO relapse frequency, such as azathioprine or rituximab.

Conclusions

ABS represents an inaugural or limited form of NMO in a high proportion of anti-AQP4 (+) patients.

Abbreviations

ABS: Acute brainstem syndrome; AQP4: Aquaporin 4; CSF: Cerebrospinal fluid; EDSS: Expanded Disability Status Scale; MRI: Magnetic resonance imaging; NMO: Neuromyelitis optica; NMOSD: NMO spectrum disorder; OCB: Oligoclonal bands

Funding

This work was supported by grant (to Y Jiang) from the Medical Research Foundation of Guangdong Province (A2014233) and the Natural Science Foundation of Guangdong Province (2016A030313228). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

All the data supporting our findings is contained within the manuscript.
Authors' contributions

YJ, XH and CC had full access to all of the data in this study and are responsible for the data integrity and the accuracy of the data analysis. The authors' contributions are as follows: Study concept and design: YJ, CC and XH; Data acquisition: CC, YI and YD; Data analysis and interpretation: CC, YI, ZK and FG. Manuscript drafting: CC, YJ and XL; Statistical analysis: CC, YJ and FG; and study supervision: YJ, XH. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This research was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-Sen University. All participants involved in this study provided written informed consent. Data acquisition: CC, YJ and YD; Data analysis and interpretation: CC, YJ, ZK and FG. Manuscript drafting: CC, YJ and XL; Statistical analysis: CC, YJ and FG; and study supervision: YJ, XH. All authors read and approved the final manuscript.

Author details

1Department of Neurology, The Affiliated Hospital, Hangzhou Normal University, 136 Wenzhou Road, Hangzhou, Zhejiang 310015, People’s Republic of China. 2Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, People’s Republic of China. 3Department of Chemical and Environmental Engineering, University of Nottingham, 199 Taikang East Road, Ningbo, Zhejiang 315100, People’s Republic of China. 4Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, People’s Republic of China.

Received: 29 January 2016 Accepted: 15 October 2016

Published online: 21 October 2016

References

1. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weisenerken BG. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.
2. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weisenerken BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14.
3. Lennon VA, Wingerchuk DM, Kyzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weisenerken BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.
4. McFarling DA, Susac JO. Hoquet diabolique: intractable hiccups as a manifestation of multiple sclerosis. Neurology. 1979;29:707–801.
5. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weisenerken BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390–6.
6. Misu T, Fujihara K, Nakashima I, Miyazawa I, Okita N, Takose S, Itoyama Y. Pure optic-spinal form of multiple sclerosis in Japan. Brain. 2002;125:2460–8.
7. Kim H, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH, Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neuro. 2015;84:1165–73.
8. Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, Qiu W, Hu X, Lu Z. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neuro. 2014;261:954–62.
9. Li Y, Jiang B, Chen B, Zhao M, Zhou C, Wang S, J, Wang R. Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report. Neuro Sci. 2015;Apr 3. [Epub ahead of print]
10. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takay S, Collongues N, Banwell B, Fujihara K, de Seze J. Brainstem manifestations in neuromyelitis optica: a multicenter study of 238 patients. Mult Scler. 2014;20:843–7.
11. Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho JW. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432–9.
12. Wang KC, Lee CL, Chen St, Lin KH, Tsai CP. Prominent brainstem symptoms/signs in patients with neuromyelitis optica in a Taiwanese population. J Clin Neurosci. 2011;18:1197–200.
13. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periapicalcutal lesions in neuromyelitis optica. Neurology. 2005;65:1479–82.
14. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weiand SD, Cabrera-Gómez JA, Newell K, Mandler RN, Pittock SJ, Weisengerken BG, Lucchinetti CF. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76:1229–37.
15. Jarius S, Ruprecht K, Wildemann B, Kruempel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Liner R, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Masznik M, Hoffmann F, Schiippinger S, Fais JH, Neuhaus O, Etrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pelkober H, Ziemann U, Kern P, Wånderger K, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zett L, Meier C, Wilke C, Hartung HP, Aktas O, Paul F. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre of 175 patients. J Neuroinflammation. 2012;9:14.
16. Nino M, Uesugi H, Takahashi T, Fukazawa T, Minami N, Tashiro J, Fukiji N, Doi S, Kikuchi S. Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder. Intern Med. 2012;51:809–12.
17. Asgari N, Skjeie HP, Lillevang ST, Steenstrup T, Stenager E, Kyvik KO. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol. 2013;13:33.
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weisengerken BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–9.
19. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandoll-Berwold M, Thompson AJ, Waubant E, Weisengerken B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011;69:929–32.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
21. Chalumeau-Lemoine L, Chretien F, Gaëlle Si Larbi A, Brugieres P, Gray F, Brun-Buisson C, Creange A. Devic disease with brainstem lesions. Arch Neurol. 2006;63:591–3.
22. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, Tobita M, Itoyama Y. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79:1075–8.
23. Lu Z, Zhang B, Qiu W, Kang Z, Shen L, Long Y, Huang J, Hu X. Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One. 2011;6:e22766.
24. Marignier R, De Seze J, Vukusic S, Durand-Dubief F, Zéphir H, Vermersch P, Cabre P, Cavillon G, Honnorat J, Confavreux C. NMO-IgG and Devic’s neuromyelitis optica: a French experience. Mult. Scler. 2008;14:440–5.
25. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. Aquaporin-4 modifications in neuromyelitis optica (NMO): An Italian series of 33 patients. Neuro. 2007;254:1233–7.
26. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig H, Hoffeld R, Vincent A, Zipp F. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;4:e133.
27. Weisengerken B, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 2006;59:566–9.
28. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hoffeld R, Vincent A. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007;68:1076–7.
29. Matsuoka T, Matsushita T, Kawano Y, Oseogawa M, Ochi H, Ishizu T, Minohara M, Kikuchi H, Mihara F, Ohyagi Y, Kira J. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain. 2007;130:206–23.

30. Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol. 2006;63:398–400.

31. Alverenga MP, Alverenga RM, Alverenga MP, Santos AM, Thuler LC. Anti-AQP4(4) antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis. J Spinal Cord Med. 2012;35:251–5.

32. Chang KH, Lyu RK, Chen CM, Wu YR, Chang HS, Huang CC, Kuo HC, Chu CC, Hsu WC, Ro LS. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. Mult Scler. 2013;19:299–307.

33. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197–200.

34. Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Francotte D, Rupiecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298:158–62.

35. Cabrera-Gómez JA, Bonnani M, González-Quevedo A, Saiz-Hinarejos A, Marignier R, Olindo S, Graus F, Smadja D, Merle H, Thomas L, Gómez-Garcia A, Cabre P. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler. 2009;15:828–33.

36. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e163.

37. Kitley J, Waters P, Woodhall M, Leite M, Murchison A, George J, Küker W, Chandrate S, Vincent A, Palace J. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276–83.

38. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takashiki T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Lin AM, Misu T, Leite M, Aoki M, Fujihara K. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–8.

39. Probstel AK, Rudolf G, Domnair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46.

40. Dale RC, Tantsis EM, Merheb V, Kumaran RY, Sinnaz N, Pathmanandavel K, Ramanathan S, Booth DR, Wienholt LA, Prekog K, Clark DR, Guillemain GI, Lim CK, Mathew BK, Britz F. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e12.

41. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter J, Akdas O, Kämpfel T, Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1–16.

42. Kim SH, Kim W, Li XF, Jung U, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18:1480–3.

43. Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Akdas O, Kämpfel T, Krumholz K, Trebst C, Paul F, Pache F, Obemann M, Zeltner L, Schwab M, Berthele A, Jarius S, Kleiter J, Neuromyelitis Optica Study Group (NEMOS). Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol. 2016;263:575–82.

44. Kleiter J, Hellwig K, Berthele A, Kämpfel T, Linker RA, Hartung HP, Paul F, Akdas O, Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:293–45.

45. Min HJ, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18:113–5.